Hepatitis C - 8 Clinical Trials For: Sofosbuvir (GS-7977)

Recruiting -Verified January 2013
                     
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for the Treatment of HCV
       

Condition:	Chronic Hepatitis C Virus
Interventions:	Drug: Sofosbuvir/GS-5885 400/90 mg;   Drug: Ribavirin

Recruiting - Verified December 2012
                     
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin in HCV Genotype 1 Subjects
       

Condition:	Chronic Hepatitis C Virus
Interventions:	Drug: Sofosbuvir/GS-5885 400/90 mg;   Drug: Ribavirin

Recruiting - Verified October 2012
                     
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
       

Condition:	Chronic Hepatitis C Virus
Interventions:	Drug: Sofosbuvir/GS-5885 400/90 mg;   Drug: Ribavirin

Recruiting - Verified October 2012
                     
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
       

Condition:	Hepatitis C Virus
Interventions:	Drug: Sofosbuvir; Drug: Ribavirin (RBV)

Recruiting - Verified December 2012
                     
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
       

Condition:	Chronic Hepatitis C Infection
Interventions:	Drug: PSI-7977; Drug: Ribavirin;  Drug: Pegylated-Interferon;   Drug: GS-5885;  Drug: GS-9669;  Drug: Sofosbuvir/GS-5885 400/90 mg

Recruiting - Verified October 2012
                     
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
       

Condition:	Hepatitis C
Interventions:	Drug: GS-7977 + RBV; Drug: GS-7977 placebo + RBV placebo

Recruiting - Verified December 2012
                     
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
       

Conditions:	Hepatitis C;   Cirrhosis;   Portal Hypertension;   With or Without Liver Decompensation
Interventions:	Drug: GS-7977;  Drug: Ribavirin

Recruiting - Verified December 2012
                     
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
       

Conditions:	Recurrent Chronic Hepatitis C Virus;   Post Liver Transplant
Interventions:	Drug: GS-7977;  Drug: Ribavirin

Additional Links:
 

Clinical Trial Updates

ClinicalTrials.gov: updated in the last 30 days

NATAP

First ever successful use of Daclatasvir and GS-7977 (Sofosbuvir) , an IFN-free regimen, in a Liver Transplant recipient with severe recurrent Hepatitis C

 
MedPage Today

HCV Studies Give Hope for Interferon-Free Therapy

New England Journal Of Medicine

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection.
Download Full Text Here

Liver Specialists of Texas
Hepatitis C Research Opportunities with Dr. Joseph Galati: 2013

Listed below are the updated hepatitis C research protocols that Liver Specialists of Texas and Dr. Galati are currently conducting. The studies are in various stages of enrollment, and some may have already met the limit of how many patients we can enroll. A PDF version is available here.

New studies are being added every few weeks, so depending on your situation, and past experience with hepatitis C treatment, new opportunities may be available soon.

Currently, the ongoing studies are making use of both interferon based therapies, as well as interferon-free therapies. It is probable that the next wave of FDA approvals will be for the interferon-free protocols.

Kindly call Dee Wade at 713-794-0700 to inquire about hepatitis C research opportunities.

Source